drugset / Trial / NCT03108300
Use of Propranolol Hydrochloride in the Treatment of Metastatic STS
NaSingle-groupOpen-labelTreatment
Summary
Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily. * The primary end point : To assess Progression Free Survival (PFS) * The secondary end points : To assess Overall Survival (OS) and Toxicity Profile
Timeline
- Start
- 2019-08-30
- Primary completion
- 2020-08-30
- Completion
- 2021-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Propranolol | Small molecule | 40 mg | — |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Other |